Abstract 2834
Background
Study 8 [NCT01972217] was a randomized Phase II trial that tested the hypothesis that the combination of PARP inhibition plus abiraterone benefits unselected patients (pts) with mCRPC. The primary endpoint was progression-free survival. A key secondary objective was to understand the relationship between HRRm status and outcome, which was challenged by low-tissue acquisition and high-test failure. The primary biomarker analysis focused on testing plasma when tumour data were not available and germline mutations were not evident. Here we describe additional analyses of circulating tumour DNA (ctDNA) to further characterize HRRm status and evaluate concordance between different testing modalities.
Methods
Tumour specimens were sequenced via Foundation Medicine. Germline analysis was performed via Color Genomics. An inhouse (RUO) sequencing assay was used for baseline ctDNA analysis. A subset of plasma samples was analyzed via GuardantOMNI™ and a custom assay (Resolution Bioscience). CtDNA libraries were also subjected to shallow whole genome sequencing (∼4–5x). From 142 enrolled pts, we obtained HRRm data for 136 (from any source).
Results
Previous tumour/germline analyses identified 8 HRRm pts: 1 somatic, 7 germline (tumour success rate 38/68 [56%]; germline success rate 102/102). CtDNA analyses yielded a success rate of 93% (127/136 pts with plasma analyzed), with tumour variants detectable with high confidence in 79% (100/127). Plasma sequencing identified additional HRRm pts, including homozygous deletions, approximately tripling the number known to have a HRRm. Plasma testing in pts with tumour data revealed high concordance between tumour and ctDNA.
Conclusions
Comprehensive, sensitive sequencing of ctDNA for HRRm is feasible in mCRPC pts with a high success rate. Both targeted and whole genome approaches add value. There was good concordance across testing modalities where gene coverage overlapped, highlighting the considerable value of ctDNA testing in mCRPC where access to tissue of sufficient quality for molecular analysis is challenging, and somatic alterations are common. The first two authors contributed equally.
Clinical trial identification
NCT01972217.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Editorial Acknowledgement
n/a
Disclosure
T.H. Carr, C. Adelman, A. Barnicle, I. Kozarewa, S. Luke, Z. Lai, S. Menon, B. Dougherty, E.A. Harrington, J.C. Barrett, C. Goessl, D. Hodgson: Employee and stockholder: AstraZeneca. S. Hollis: Contracted: AstraZeneca and own stock. F. Saad: Grants and personal fees: AstraZeneca, Janssen, Astellas, Sanofi, Bayer. N. Sala: Personal fees: Astellas, Janssen, Bristol-Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract